复发/难治性 CD5 阳性弥漫大 B 细胞淋巴瘤的 CAR T 细胞治疗较标准治疗产生更有利的结局
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.
FRONTIER PAPERS
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.
Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy.
T细胞淋巴瘤(TCL)是一组异质性恶性肿瘤,治疗选择有限,预后较差。
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
双特异性CAR-T 细胞疗法在晚期B细胞恶性肿瘤的临床试验中显示出有希望的结果。
Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive ana
这些结果表明抗CD5 CAR-T细胞可在r/r ALK+ ALCL患者中诱导临床反应。此外,本病例强调了在CAR-T细胞治疗的临床实验室诊断和预后中,利用高灵敏度和高准确度的先进技术进行生物学检测的重要性。
Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profil
PB替代BM监测PTCLs肿瘤负荷或MRD的灵敏度高达85.71%,可缓解临床采样的巨大压力,提高患者依从性。
Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.
我们回顾性分析了 2022 年 1 月至 2024 年 12 月在我中心接受治疗的 118 例新诊断 FL 患者。
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
复发或难治性 T 细胞急性淋巴细胞白血病/淋巴瘤(r/r T-ALL/LBL)常具有侵袭性,且与不良预后相关。
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
T 细胞急性淋巴细胞白血病/淋巴瘤(T-ALL/LBL)是一种起源于祖 T 细胞的侵袭性恶性肿瘤。
Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell
我们在新型靶向药物时代建立了一株新的 ENKTL 细胞系。
A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.
这些结果提示,儿童和青少年NKTCL的组织病理学和免疫组化特征与成人病例相似。
MEMBER ACCOUNT
登录成功会直接打开下一页。